Sorrento Therapeutics (SRNE) News Today $0.0007 0.00 (-12.50%) (As of 12/24/2024 02:38 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesOptions ChainSEC FilingsSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated by Analysts at StockNews.comDecember 25 at 2:19 AM | americanbankingnews.comStockNews.com Initiates Coverage on Sorrento Therapeutics (NASDAQ:SRNE)December 18, 2024 | americanbankingnews.comSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSorrento Therapeutics Inc SRNEApril 26, 2024 | morningstar.comJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy CaseMarch 12, 2024 | wsj.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | tmcnet.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comSorrento Therapeutics (NASDAQ:SRNE) Stock Price Passes Below 200 Day Moving Average of $0.11Sorrento Therapeutics (NASDAQ:SRNE) Stock Crosses Below 200 Day Moving Average of $0.11February 9, 2024 | marketbeat.comSorrento Therapeutics, Inc. (0L85.L)January 9, 2024 | finance.yahoo.comSorrento Therapeutics Inc SRNEQNovember 5, 2023 | morningstar.comSorrento, Italy - Weather Forecasts | Maps | News - Yahoo WeatherOctober 14, 2023 | yahoo.comCourt rules Virpax CEO Anthony Mack breached his agreement with Sorrento TherapeuticsSeptember 7, 2023 | bizjournals.comSorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse BidAugust 8, 2023 | finance.yahoo.comWildcat Claims CNSL Shareholders Are Being Ripped Off in Weak Deal, Claiming $14 Price is RequiredJuly 13, 2023 | msn.comSorrento sees promising phase 2 results for abivertinib for lymphomaJuly 5, 2023 | seekingalpha.comSRNEQ Sorrento Therapeutics, Inc.June 22, 2023 | seekingalpha.comSorrento Therapeutics (OTC: SRNE.Q)June 14, 2023 | fool.comUBS Group AG Has $2.12 Million Stock Position in Sorrento Therapeutics, Inc. (NASDAQ:SRNE)UBS Group AG increased its stake in shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE - Get Rating) by 916.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,383,825 shares of the biopharmaceutical company's stock after acquiring an addiJune 6, 2023 | marketbeat.comSorrento Therapeutics, Inc. (SRNEQ)April 24, 2023 | finance.yahoo.comSorrento Therapeutics Opponent Loses Chapter 11 Committee SeatMarch 21, 2023 | wsj.comFirm Retention Summary: Sorrento Therapeutics Inc.March 18, 2023 | wsj.comWhy Sorrento Therapeutics (SRNE) Stock Plummeted TodayMarch 15, 2023 | thestreet.comSorrento Therapeutics, Inc. (NASDAQ:SRNE) Shares Bought by Credit Suisse AGCredit Suisse AG grew its holdings in Sorrento Therapeutics, Inc. (NASDAQ:SRNE - Get Rating) by 260.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,026,474 shares of the biopharmaceutical company's stock after buyingMarch 8, 2023 | marketbeat.comIs a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?March 2, 2023 | finance.yahoo.comScilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain managementFebruary 27, 2023 | finance.yahoo.comWhy Sorrento Therapeutics Stock Is Soaring TodayFebruary 22, 2023 | benzinga.comBankrupt Sorrento Therapeutics Secures Court Approval for $75M FinancingFebruary 22, 2023 | yahoo.comSorrento Therapeutics surges 28% as court nods for a $75M loanFebruary 22, 2023 | seekingalpha.comSorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 CaseFebruary 21, 2023 | finance.yahoo.comSorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)February 18, 2023 | finance.yahoo.comThinking about buying stock in Esports Entertainment, Marathon Digital, Sorrento Therapeutics, Nu Holdings, or ContextLogic?February 17, 2023 | benzinga.comWhy Kim Jong Un’s Daughter Is All Over North Korean MediaFebruary 15, 2023 | finance.yahoo.comSorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerFebruary 14, 2023 | finance.yahoo.comSorrento Therapeutics Files For BankruptcyFebruary 14, 2023 | uk.finance.yahoo.comHot Stocks: TDC climbs on earnings; FSLY upgrade; TWLO restructuring; SRNE bankruptcyFebruary 13, 2023 | seekingalpha.comSorrento Therapeutics Files for Bankruptcy to Halt $173 Million Licensing JudgmentsFebruary 13, 2023 | wsj.comSorrento Therapeutics stock plummets more than 60% on news of bankruptcy filingFebruary 13, 2023 | proactiveinvestors.comSorrento Therapeutics Stock Is Sinking: What's Going On?February 13, 2023 | markets.businessinsider.comSorrento Therapeutics Stock Nosedives After Filing Bankruptcy PaperworkFebruary 13, 2023 | finance.yahoo.comJoint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.February 13, 2023 | finance.yahoo.comThinking about buying stock in Sorrento Therapeutics, Bed Bath & Beyond, C3.ai, Expion360, or SoundHound AI?February 13, 2023 | benzinga.comSorrento sheds 60% after bankruptcy filing (update)February 13, 2023 | msn.comA Sorrento Therapeutics, Inc. (NASDAQ:SRNE) insider increased their holdings by 2.0% last yearFebruary 13, 2023 | finance.yahoo.comScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraineFebruary 12, 2023 | finance.yahoo.comSorrento Therapeutics, Inc. (NASDAQ:SRNE) Shares Bought by Victory Capital Management Inc.Victory Capital Management Inc. increased its holdings in Sorrento Therapeutics, Inc. (NASDAQ:SRNE - Get Rating) by 136.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 281,357 shares of the biopharmaceuticFebruary 10, 2023 | marketbeat.comSG Americas Securities LLC Has $84,000 Holdings in Sorrento Therapeutics, Inc. (NASDAQ:SRNE)SG Americas Securities LLC trimmed its position in shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE - Get Rating) by 87.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,722 shares of the biopharmaceuFebruary 9, 2023 | marketbeat.com5 Hot Healthcare Stocks to Buy NowFebruary 3, 2023 | insidermonkey.comRaymond James & Associates Increases Stock Holdings in Sorrento Therapeutics, Inc. (NASDAQ:SRNE)Raymond James & Associates boosted its stake in Sorrento Therapeutics, Inc. (NASDAQ:SRNE - Get Rating) by 65.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 257,319 shares of the biopharmaceutical company'February 3, 2023 | marketbeat.comSorrento Issues Supplement to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common StockFebruary 3, 2023 | wsj.com Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address After New Years, price goes back up 4,800% (Ad)When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore! Click here to review Tim’s special Holiday offer before it’s too late. SRNE Media Mentions By Week SRNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRNE News Sentiment▼0.000.58▲Average Medical News Sentiment SRNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRNE Articles This Week▼10▲SRNE Articles Average Week Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bon Natural Life News Today Virpax Pharmaceuticals News Today Galera Therapeutics News Today Panbela Therapeutics News Today Oncternal Therapeutics News Today Trevena News Today Kiromic BioPharma News Today Eterna Therapeutics News Today Revelation Biosciences News Today ASLAN Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRNE) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
